R1 RCM Inc

R1 RCM — Q3 2018 Earnings Presentation

15 slides from R1 RCM's earnings presentation, Nov 7, 2018

  1. Slide 1: Third Quarter 2018 Results Conference Call

    Exhibit 99.2 Third Quarter 2018 Results Conference Call November 7, 2018

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures

    Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute “forward-looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future, not pa

  3. Slide 3: Q3 2018 Financial Highlights

    Q3 2018 Financial Highlights ▪ Revenue of $250.4 million, up $127.2 million year-over-year ▪ GAAP net loss of $13.4 million compared to net loss of $3.6 million in Q3’17 ▪ Adjusted EBITDA of $20.4 million, up $17.3 million year-over-year ▪ 2018 guidance unchanged: Revenue of $850-900 million, and ad

  4. Slide 4: Digital Transformation Office (DTO)

    Digital Transformation Office (DTO) ▪ Highlights ▪ DTO goal is to systematically automate manual tasks across the revenue cycle ▪ Staffed with dedicated internal talent, augmented by best-in-class advisors ▪ Increases confidence in delivering on our financial targets ▪ Over the long term, we believe

  5. Slide 5: Commercial Activity

    Commercial Activity Three Near-Term Focus Areas: ▪ Increased Sales & Marketing Efforts ▪ Translating to progression of pipeline across both end-to-end and modular discussions ▪ Increase in pro-active discussions as well as inbound RFPs ▪ Intermedix End-Markets ▪ Increased sales momentum across Inter

  6. Slide 6: Customer Onboarding Update

    Customer Onboarding Update ▪ Intermountain Healthcare ▪ Rationalized 35% of targeted third-party vendor spend ▪ Centralized 80% of billing work relative to target ▪ Standardized 73% of functions to R1 standard operating methods ▪ Ascension Phase-3 ▪ Started onboarding in early July ▪ Technology go-l

  7. Slide 7: 3Q'18 non-GAAP Results – Q/Q and Y/Y Comparison

    3Q’18 non-GAAP Results – Q/Q and Y/Y Comparison ($ in millions) 3Q’18 2Q’18 3Q’17 Key change driver(s) • Q/Q: Full quarter of contribution from Intermedix and Intermountain Revenue $250.4 $207.9 $123.2 • Y/Y: New customers onboarded in last twelve months and Intermedix • Q/Q and Y/Y: Full quarter of

  8. Slide 8: Additional Commentary

    Additional Commentary ▪ Net debt of $325.3 million as of 9/30/18, including restricted cash ▪ Expect to start paying down debt with cash from operations in mid-2019 ▪ Net interest expense of $10.0 million in Q3’18 ▪ Interest on subordinated debt paid in cash, did not exercise payment-in-kind option

  9. Slide 9: Financial Outlook

    Financial Outlook1 ($ in millions) 2018 Outlook 2020 Outlook Revenue $850 – $900 $1,200 – $1,300 GAAP Operating Income ($30)-($50) $115 – $155 Adjusted EBITDA $50 – $55 $225 – $250 NPR2 growth assumptions – $B Intermountain Health $4.6 Presence Health $2.2 AMITA Health $1.8 Ascension Medical Group $

  10. Slide 10: Appendix

    Appendix

  11. Slide 11: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance mea

  12. Slide 12: Reconciliation of GAAP Net Income (Loss) to non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Income (Loss) to non-GAAP Adjusted EBITDA n.m. – not meaningful Due to rounding, numbers presented in this table may not add up precisely to the totals provided. 12

  13. Slide 13: Reconciliation of GAAP to non-GAAP Financials

    Reconciliation of GAAP to non-GAAP Financials Reconciliation of GAAP Cost of Services to Non-GAAP Cost of Services $ in millions Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 (Unaudited) (Unaudited) Cost of services $ 219.3 $ 111.8 $ 547.9 $ 289.1 Less: Share-b

  14. Slide 14: Reconciliation GAAP Operating Income Guidance to non-GAAP Adjusted EBITDA Guidance

    Reconciliation GAAP Operating Income Guidance to non-GAAP Adjusted EBITDA Guidance 2018 and 2020 Outlook $ in millions 2018 2020 GAAP Operating Income Guidance ($30)-($50) $130-$170 Plus: Depreciation and amortization expense $25-$30 $35-$45 Share-based compensation expense $15-$20 $20-$25 Amortizat

  15. Slide 15: Net Debt as of 9/30/18

    Net Debt as of 9/30/18 $ in millions June 30, September 30, 2018 2018 (Unaudited) (Unaudited) Long-term debt $ 270.0 $ 270.0 Subordinated notes 110.0 110.0 380.0 380.0 Less: Cash and cash equivalents 38.8 52.4 Current portion of restricted cash 2.0 1.8 Non-current portion of restricted cash equivale

R1 RCM — Q3 2018 Earnings Presentation on 6ix